A critical review of cholinesterase inhibitors as a treatment modality in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Early research into Alzheimer's disease launched the cholinergic hypothesis, based on the correlation between central cholinergic deficiency and clinical measures of cognitive decline. This was epitomized in therapeutic strategies employing a variety of procholinergic agents, of which only the inhibitors of cholinesterase (ChE), the enzyme thai hydrolyzes acetylcholine in the synaptic cleft, have been proven clinically viable. Five such agents are reviewed: tacrine and donepezil, which act at the ionic subsite of acetylcholinesterase (AChE), and rivastigmine, galantamine, and metrifonate, which act at its catalytic esteratic subsite. Despite statistical evidence of efficacy from numerous well-controlled multicenter trials, important clinical utility issues remain outstanding: (i) number-needed-to-treat (NNT) analyses, quantifying the number of patients needing to be treated for one patient to show benefit, find values of 3 to 20; (ii) the pivotal trials themselves were conducted in nonrepreseniative populations, largely comprised of physically healthy outpatients with mildto-moderate Alzheimer's disease and a mean age of 72 years (thereby excluding over 30% of typical Alzheimer patients in State of California-funded clinics), treated for up to 6 months; and (Hi) tolerability is underreported and characterized by a positive correlation between dose, effect and cholinergic side effects - potentially serious adverse events include bradycardia, anorexia, weight loss and myasthenia with respiratory depression. Therapies thus require titration and constant monitoring. Nevertheless, acetylcholinesterase inhibitors (AChEls) constitute the first class of effective agents and are likely to remain so in the continuing absence of viable alternatives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T., & Donepezil Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.136 · Cited by 1,618
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
The incidence of dementia: A meta-analysis
Jorm, A. F., & Jolley, D. (1998) · Neurology · doi:10.1212/wnl.51.3.728 · Cited by 903
Nitsch, R. M., Slack, B. E., Wurtman, R. J., & Growdon, J. H. (1992) · Science · doi:10.1126/science.1411529 · Cited by 898
Raskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870
Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease
Watkins, P. B. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510370044030 · Cited by 829
Cholinesterase Inhibition for Alzheimer Disease: A Meta-analysis of the Tacrine Trials
Qizilbash, N., Whitehead, A., Higgins, J., Wilcock, G., Schneider, L., Farlow, M., & for the Dementia Trialists' Collaboration (1998) · JAMA · doi:10.1001/jama.280.20.1777 · Cited by 161 · cited 1×
“001).(7) The number requiring treatment to be discontinued because of liver enzyme increases is much lower in practice than in clinical trials, since 87% of those rechallenged were able to tolerate and continue tacrine.”
ResultSelf-citation
Cited by
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
McHardy, S. F., Wang, H.-Y. L., McCowen, S. V., & Valdez, M. C. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1272571 · Cited by 163
“Patients treated with AChE inhibitors also do not experience a complete reversal of the symptoms, but many do experience a slowed progression of symptoms for a period of time [24].”
BackgroundNatural Phytochemicals in the Treatment and Prevention of Dementia: An Overview
Libro, R., Giacoppo, S., Soundara Rajan, T., Bramanti, P., & Mazzon, E. (2016) · Molecules · doi:10.3390/molecules21040518 · Cited by 107
“In 2000 RIV (Exelon®) was approved by the FDA as a transdermal patch [127] to treat mild to moderate AD [128], and as of 2014, it has been used for the treatment of AD in more than 90 countries worldwide.”
MethodWalnut Oil Prevents Scopolamine-Induced Memory Dysfunction in a Mouse Model
Liao, J., Nai, Y., Feng, L., Chen, Y., Li, M., & Xu, H. (2020) · Molecules · doi:10.3390/molecules25071630 · Cited by 53
Deng, G., Wu, C., Rong, X., Li, S., Ju, Z., Wang, Y., Ma, C., Ding, W., Guan, H., Cheng, X., et al. (2019) · Phytomedicine · doi:10.1016/j.phymed.2019.153007 · Cited by 34
Metadata
- Authors
- S. Schneider, L.
- Venue
- Dialogues in Clinical Neuroscience
- Publisher
- Informa UK Limited
- Published
- 2000-06-30
- Volume
- 2
- Issue
- 2
- Pages
- 111-128
- ISSN
- 1294-8322 (ISSN-L)
- 1958-5969
- OpenAlex
- W4297734373
- Cited by
- 97
- References
- 7
- FWCI
- 0.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.